Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany
Authors:
Open Access
- 16 February 2026
- journal article
- research article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 27 (7) , 1-10
Abstract
Objectives: Letermovir has demonstrated efficacy and tolerability as prophylaxis against clinically significant cytomegalovirus infection (csCMVi) in CMV-seropositive adult patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) compared to alternative antivirals. Despite these advantages, associated costs remain substantial. This study addresses the evidence gap by evaluating the health economic impact of CMV prophylaxis with letermovir in a real-world setting for alloHCT patients. Methods: This retrospective, multi-centre case-control study was conducted at six German tertiary care centres. A micro-costing approach evaluated hospitalisation and anti-CMV drug acquisition costs over a 48-week follow-up period post-alloHCT. The analysis included patients surviving at least 100 days following alloHCT, comparing individuals receiving letermovir prophylaxis (cases) with those who did not (controls) between January 2018 and April 2021. Results: The incidence of csCMVi was significantly higher in the control than in the letermovir group (56%, n = 98 vs. 34%, n = 63, p < 0.001). Median hospital length of stay was significantly longer in the control group (45 days, IQR 36–66) compared to the letermovir group (39 days, IQR 32–55; p < 0.001). Hospitalisation costs were comparable ( p = 0.865), while anti-CMV drug acquisition and overall direct treatment costs were significantly higher in the letermovir group (€21,844, 95% CI 19,247 − 25,107 vs. €7,711, 95% CI 12,692 − 25,107, p < 0.001; 81,871, 95% CI 76,721 − 87,021 vs. 67,161, 95% CI 61,693 − 72,629, p < 0.001). Besides letermovir, cost drivers post-alloHCT were rehospitalisation and csCMVi. Conclusions: Our study demonstrated higher anti-CMV drug acquisition costs and overall direct treatment costs in patients receiving letermovir prophylaxis compared to controls. However, these higher costs are accompanied by significantly improved clinical outcomes.Keywords
Funding Information
- Universitätsklinikum Köln
This publication has 23 references indexed in Scilit:
- Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational studyJournal of Infection, 2024
- Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2024
- Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United StatesPharmacoEconomics - Open, 2023
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsValue in Health, 2022
- Cost‐effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspectiveJournal of Medical Virology, 2020
- Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantationSupportive Care in Cancer, 2020
- Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive StrategyTransplantation and Cellular Therapy, 2019
- The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approachesCytotherapy, 2014
- Costs of Allogeneic Hematopoietic Cell Transplantation with High-Dose RegimensTransplantation and Cellular Therapy, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007